Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial.
暂无分享，去创建一个
B. Zinman | C. Wanner | M. Cooper | S. Inzucchi | M. von Eynatten | S. Hantel | A. Koitka‐Weber | M. Cooper
[1] B. Zinman,et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. , 2017, The lancet. Diabetes & endocrinology.
[2] M. Jardine,et al. Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects. , 2017, Journal of the American Society of Nephrology : JASN.
[3] P. Heagerty,et al. Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014. , 2016, JAMA.
[4] John M Lachin,et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. , 2016, The New England journal of medicine.
[5] B. Zinman,et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.
[6] B. Kasiske,et al. Diabetic Kidney Disease– A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO) , 2014, Kidney international.
[7] H. Heerspink,et al. The effect of RAAS blockade on the progression of diabetic nephropathy , 2014, Nature Reviews Nephrology.
[8] B. Kestenbaum,et al. Kidney disease and increased mortality risk in type 2 diabetes. , 2013, Journal of the American Society of Nephrology : JASN.